LL-37 Research Guide

Full name: Cathelicidin Antimicrobial Peptide LL-37

A human cathelicidin antimicrobial peptide with broad-spectrum activity against bacteria, viruses, and fungi. Also promotes wound healing and modulates innate immune response.

How LL-37 Works

Disrupts microbial membranes, neutralizes endotoxins, recruits immune cells via chemotaxis, and promotes angiogenesis and re-epithelialization.

Dosing Protocol

• Typical dose: 50-100 mcg
• Frequency: Daily
• Duration: 2-6 weeks
• Route: Topical or subcutaneous injection

Reported Benefits

• Broad-spectrum antimicrobial
• Wound healing acceleration
• Biofilm disruption
• Immune system enhancement

Potential Side Effects

• Local irritation
• Redness at application site
• Mild inflammatory response

Research Citations

1. LL-37 in wound healing and infection control (2021) - Enhanced wound closure rates and reduced bacterial colonization in chronic wound models.
2. Cathelicidin peptides as innate immune modulators (2019) - Demonstrated ability to shift macrophage polarization toward pro-healing M2 phenotype.

Related Healing & Recovery Compounds

• BPC-157 - Full Profile
• TB-500 - Full Profile
• Pentosan Polysulfate - Full Profile
• KPV - Full Profile
• Thymosin Beta-4 - Full Profile
• BPC-157 (Oral) - Full Profile

View full LL-37 profile with 3D molecule viewer →